Spero Therapeutics, Inc.
SPRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001701108
No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Spero Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 50 | 59 | +9 |
| Shares | 20.6M | 21.4M | +804.5K (+3.9%) |
| Value | $48.3M | $47.5M | −$808.9K (−1.7%) |
New holders (21)
Institutions that held Spero Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
Sold out (12)
Institutions that held Spero Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Anson Funds Management LP | 421,956 | $987.4K |
| Citadel Advisors LLC | 376,458 | $880.9K |
| Squarepoint Ops LLC | 194,301 | $454.7K |
| Marshall Wace, LLP | 157,072 | $367.5K |
| Quadrature Capital Ltd | 40,128 | $93.9K |
| Omers Administration Corp | 39,400 | $92.2K |
| Schonfeld Strategic Advisors LLC | 20,314 | $47.5K |
| Occudo Quantitative Strategies LP | 16,421 | $41.2K |
| Intrepid Family Office LLC | 16,279 | $38.1K |
| Torrey Growth & Income Advisors | 17,025 | $37.6K |
| BNP Paribas Arbitrage, SA | 40 | $94 |
| Caitong International Asset Management Co., Ltd | 3 | $7 |